The development of novel cell therapies requires the latest technologies to create, isolate and characterize the highest value cells. As cell-based therapies expand into areas far beyond monoclonal antibodies, cell line development researchers look for new tools to engage and manage their expanding remit.
Cell line development workflows engage in isolation of single cells (‘clonal derivation’) followed by outgrowth. Productivity measurements and critical quality attributes are employed in the characterization of leading clones for banking in Master Cell Banks.
This webinar explores our two new technologies for cell line development, ICON™ and STUDIUS™. Learn about the practicalities of integrating data-centric decision making into the cell therapy development process and how new levels of assurance, data integrity and process management can build into a more confident investigational new drug (IND) submission.
Please fill out the form to view this content.
